1. Scrip
  2. >>Business

Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO

 
• By Mandy Jackson

Moderna is in no rush to conduct an IPO, but the secretive biopharma unicorn gave potential investors in a future offering a glimpse of its 12 programs in or nearing the clinic at J.P. Morgan’s annual conference.

LabmicroscopeDNAgel_1200x675

Moderna Therapeutics LLC has become one of the biopharmaceutical industry’s biggest unicorns – attracting billions of dollars in venture, partnership and grant funding – while revealing few details about its messenger RNA (mRNA) therapeutic platform. But the normally secretive company subjected its pipeline to public scrutiny during an appearance at the J.P. Morgan Healthcare Conference.

Scrip spoke with Moderna CEO Stephane Bancel about before and after the standing-room-only Jan. 9 J.P. Morgan presentation, which was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.